Novavax has reported a net loss of $7.22m, or $0.05 per share, for the third quarter ended 30 September 2012 compared to a net loss of $3.21m, or $0.03 per share, for the third quarter ended 30 September 2011.
Revenue for third quarter of 2012 was $5.76m compared to $5.01m for the third quarter of 2011.
The company reported a net loss of $20.47m, or $0.16 per share, for the nine months ended 30 September 2012 compared to a net loss of $15.66m, or $0.14 per share, for the nine months ended 30 September 2011.
Revenue of $17.51m was reported for the first nine months of 2012 compared to $8.84m for the first nine months of 2011.
Novavax president and chief executive officer Stanley Erck said the positive results from the Phase I trials of H5N1 influenza vaccine candidate and the advancement of RSV vaccine candidate into new clinical trials are allowing the company to advance with its development partners, BARDA and PATH.
"These programs have also gained the financial support of sophisticated life-science institutional investors whose recent investments improve our capital position that is expected to fund our operations for at least the next two years," Erck added.